MRK Merck & Company, Inc. Common St

+0.51  (1%)
Previous Close 64.04
Open 64.00
Price To book 4.41
Market Cap 176.55B
Shares 2,735,164,000
Volume 5,734,591
Short Ratio 1.87
Av. Daily Volume 9,064,760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review Sept. 22, 2017.
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 various presentations (5) at ASCO June 3-5, 2017. Abstracts 9014, 4515, 4503, 3012, 6010.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
Phase 3 trial met primary endpoint - February 14, 2017.
Doravirine (MK-1439)
Approved May 18, 2017.
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
Phase 3 data due 4Q 2017.
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Fully enrolled. Data due in 2019.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016.
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 initiated June 2016. Initial data due 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
Type 2 diabetes
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due mid-2017.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 2b complete.
Chronic cough
Approval announced March 14, 2017.
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
PDUFA date May 27, 2017.

Latest News

  1. FDA Approves Merck’s Keytruda to Treat Cancers With Genetic Defects
  2. FDA clears Merck's Keytruda based on cancer genetics, not location
  3. Merck Presents Phase II Data on Chronic Cough Candidate
  4. FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer
  5. The FDA just took an entirely new approach to approving a cancer drug
  6. Merck Announces Third-Quarter 2017 Dividend
  7. Why Merck & Co. Continued to Grow in 1Q17
  8. A Close Look at Merck & Co.’s Valuation after 1Q17 Earnings
  9. UK competition watchdog accuses Merck of obstructing biosimilars
  10. FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
  11. Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing
  12. These Big Drug Stocks May Cure the Trump Blues
  13. Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
  14. Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?
  15. Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
  16. 3 Top Animal-Health Companies to Buy in 2017
  17. ETFs with exposure to Merck & Co., Inc. : May 19, 2017
  18. Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications
  19. Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union
  20. 100 Healthy Years - Are Kids Prepared?